## Drug Summary
Tipiracil hydrochloride is a component of the drug combination trifluridine/tipiracil, marketed under the name Lonsurf. It functions primarily as a thymidine phosphorylase inhibitor, enhancing the efficacy of trifluridine by inhibiting its degradation. Tipiracil hydrochloride is used in the treatment of metastatic colorectal cancer and certain types of gastric cancer. The pharmacokinetics of tipiracil involve its ability to increase the bioavailability of trifluridine by preventing its rapid metabolism, thus allowing it to exert its antineoplastic effects more effectively. Trifluridine is incorporated into DNA during replication, leading to a disruption of DNA function and cell death. The metabolism of tipiracil primarily occurs in the liver.

## Drug Targets, Enzymes, Transporters, and Carriers
Given the provided information lacks details, from general knowledge, the major pharmacological target of tipiracil is thymidine phosphorylase, the enzyme responsible for breaking down trifluridine. By inhibiting this enzyme, tipiracil allows higher levels of trifluridine to remain available, enhancing its cytotoxic effects against tumor cells. No specific transporters or carriers associated with the action or transport of tipiracil are typically noted, as its primary function is the enzymatic inhibition relevant to increasing trifluridine efficacy.

## Pharmacogenetics
As of current scientific literature, detailed pharmacogenetic factors specifically governing tipiracil hydrochloride's efficacy and metabolism are not extensively characterized. However, the enzyme thymidine phosphorylase, which it inhibits, may have genetic variations affecting its expression or function in different individuals, possibly altering the efficacy of tipiracil. Further research could illuminate specific genetic markers that predict response or resistance to treatment with trifluridine/tipiracil, contributing to more personalized therapeutic strategies. Thus, while direct pharmacogenetic associations are not specifically established, the potential for genetic variability in enzyme activity suggests a potential area for future pharmacogenetic exploration.